Join Us at the ESMO Congress 2022
September 9 – 13 | Paris, France
Meet Key Leaders of Our Oncology Team
Whether your focus is on optimizing clinical therapeutic development with a biomarker-driven strategy or seeking more information to power better care decisions, we bring together global oncology specialists, providing unique insights to support your mission to transform oncology patient care.
Schedule a meeting with us at the upcoming ESMO Congress and together, let’s collaborate on a customized plan to deliver your innovative treatment solutions to patients in need.
Don’t miss attending our onsite presentation:
Line of Therapy: Definitions and Guidelines
(As part of the special session “ESMO Adaptation of an Existing Framework for Determining Line of Therapy: A Designation Ecosystem for Oncology Practice”)
Date: 11 September 2022
Time: 8:30 a.m. – 10:00 a.m. CEST
Speaker:
Executive Medical Director, Labcorp Oncology
The experience of our key leaders in this group is outlined below:
Bill Hanlon, Ph.D.
President CDCS, Clinical Therapeutic & Regulatory Sciences and Chief Scientific Officer, Labcorp Drug Development
Bill Hanlon has responsibility for all the scientific, therapeutic, market access & regulatory expertise, patient recruitment, medical device & diagnostics development, Cell & Gene Therapy growth and digital innovation for the clinical trials business. Bill has over 30 years of scientific, drug development and business leadership experience as well as extensive background in international (US, EU, LATAM, APAC) business. Starting his career at Merck, Inc. (MSD) in 1988, he quickly advanced in responsibility, broadening his expertise in global regulatory affairs and driving strategic product development. Starting at Covance in 2012 as Head of Regulatory Affairs, his most recent role was President, Clinical Development & Commercialization Services (2018-2019).
Bill earned his Bachelor of Science degree in biochemistry from Rutgers University and his Doctor of Philosophy in biochemistry and cell biology, jointly conferred by the University of Medicine and Dentistry of NJ and Rutgers University Graduate School.
Jeff Conroy
Chief Scientific Officer, OmniSeq (now part of Labcorp Oncology)
Jeff Conroy serves as Chief Scientific Officer for Omniseq. In this role, he oversees the scientific functions of Omniseq, including Research and Development (R&D), Bioinformatics, and Information Technology. He leads business development activities with key industry and pharmaceutical partners, and oversees the development and implementation of advanced diagnostic tests from target design through analytical validation. Prior to joining OmniSeq, Jeff spent three years as Director of Genomic Technologies in the Center for Personalized Medicine at Roswell Park Comprehensive Cancer Center. While at Roswell, he also served 15 years as Co-Director of the Genomics Shared Resource, overseeing its expansion to more than 50 genomics-based service offerings and a user base of 200+ investigators per year. During his clinical and basic research career, Jeff has authored or co-authored more than 70 peer-reviewed manuscripts with a focus on genomics and molecular pathology.
Poster #4717
"Comprehensive analysis of the association between RAS mutation and immune checkpoint marker expression"
12 September 2022 11:06 AM
Poster Area, Hall 4
Ken Morrison, PhD
Executive Director Operational Strategy and Planning Oncology
Ken Morrison has more 30 years of experience in drug development, the last 5 at Labcorp Drug Development (formerly Covance). As Executive Director of Operational Strategy and Planning for Oncology, he leads a team tasked with partnering across the organization to define and establish compelling strategies aligned with our customers clinical development needs from Phase I – IV. The primary focus for his team is leveraging the internal and external resources available to ensure a robust data driven study delivery strategy is established for client needs. He also represents his team on both Global Labcorp Clinical and Cross Enterprise Oncology Leadership teams to monitor effective and efficient service implementation and execution across Labcorp’s global customer base in Oncology.
Before joining Labcorp, Ken has had a diverse career in various roles focused across pharmaceutical and device product development. Ken received his BSc in biochemistry and pharmacology from the University of Strathclyde and his PhD in pharmacology from the University of Aberdeen.
Tuc Ahmad
Scientific Director of Labcorp Drug Development
Tuc Ahmad is the Scientific Director in the Diagnostic Development team at Labcorp Drug Development and based in Europe. He has responsibility as the primary scientific contact for Biopharma clients for initial engagement on new biomarker programs focused on discovery to provide a better understanding of therapeutic targets, molecular signaling, drug biology and patient response. His role encompasses projects at all stages of the drug development lifecycle from early exploratory research and validation to clinical trial implementation and CDx development. Tuc is part of the integrated CDx team that enables the progressive development of candidate biomarkers into research-appropriate tests and market-ready companion diagnostics aligned with drug development milestones.
Alison Howell, PhD
Director, Labcorp Drug Development Product Development & Market Access Consulting
Alison Howell is a Director in LabCorp Drug Development’s Product Development & Market Access Consulting group. Alison specialises in value demonstration, delivering strategic and tactical solutions to help pharmaceutical and medical device manufacturers establish the value of their products in clinical, humanistic and economic terms to support pricing, reimbursement and uptake discussions. She has over 15 years of experience across a broad range of value demonstrations projects – from market access strategy and value message development, to delivery of communication tools of varying formats including dossiers, slide decks, printed materials, iPad applications, and internal communication toolkits. Her experience spans a wide range of therapy areas, including oncology, and lifecycle stages, from early clinical development through to commercialization. Alison graduated from the University of Edinburgh with a degree in Pharmacology and PhD in Neuroscience, and is published in both scientific and health economic journals.
Ravichandra (Ravi) Karra, MD, PhD
Senior Medical Director
Ravi Karra is Senior Medical Director in Germany. He serves as lead project physician on clients’ drug development projects, provides medical/clinical strategy for the clinical development of drugs, and serves as primary contact for disease-related medical/scientific expertise to project teams. Dr. Karra has more than 20 years of experience in patient care, clinical research, medical affairs, product launch, and product life cycle management. Before Labcorp Drug Development, he was Vice President and Global Medical Head for Rheumatology and Neurology/Pain, Grunenthal GmbH Headquarters in Aachen, Germany. He previously served as Clinical Research and Pharmacovigilance Physician for the European Organization for Research and Treatment of Cancer in Brussels, Belgium. Dr. Karra joined Labcorp Drug Develop in December 2020.
Kamal Veer Singh Saini, MD
Executive Medical Director
Kamal Veer Singh Saini, MD, is executive medical director of oncology for Labcorp Clinical Development Services, based in Brussels, Belgium. He is a board-certified medical oncologist, with an active license to practice in the U.K. He contributes to the scientific strategic leadership of the Oncology area at Labcorp and provides clinical and medical expertise to project teams and other Labcorp departments on clients’ drug development projects. He brings more than 15 years of experience in clinical research and development to Labcorp. He previously served as associate scientific director for an academic research organization and as medical advisor for Institute Jules Bordet, Brussels. The author or co-author of several peer-reviewed journal articles, he joined Labcorp in June 2015.
Carla Sterk
Executive Strategist, Product Development & Market Access Consulting, Global Regulatory Affairs
Carla Sterk has 30 years of experience in regulatory affairs, the last 7 years at Labcorp Drug Development (former Covance). As an Executive Regulatory Strategist with extensive experience in global regulatory strategy development for oncology products, she has led multiple agency interactions (FDA, EMA, national competent authorities), supported sponsors with the resolution of clinical holds, contributed to comprehensive development plans and target product profiles, successfully filed orphan drug designation and expedited programs applications, developed regulatory strategies for early access programs etc. She has experience with a broad range of investigational oncology drugs in various tumor types.
Before joining Labcorp, Carla has worked in senior regulatory roles in CROs and consultancy companies. Carla is a pharmacist by training with a degree from the University of Leuven, Belgium.
Laura Vidal, MD
Executive Medical Director
Laura Vidal, MD, is executive medical director for Labcorp Clinical Development Services, based in Madrid, Spain. Dr. Vidal is the medical head of the Oncology group in EU. She contributes to the development of Labcorp policies involving medical, safety and therapeutics; serves as point of contact for key clients on business oversight; manages relationships with investigators/sites for clinical trials; and mentors clinical research physicians and medical directors across the company. Dr. Vidal has more than 15 years of experience as a physician, clinical oncologist and medical director. Before joining Labcorp, she was executive medical director for Syneos Health in Madrid and previously served as a physician, medical oncologist and clinical trials coordinator for a hospital in Barcelona. Dr. Vidal has authored or co-authored dozens of peer-reviewed journal articles and received numerous health and research awards. She joined Labcorp in December 2020.
Visit our website to meet our expansive dedicated global team of well over 65 oncology physicians supporting the latest therapeutic and diagnostic advancements including cell & gene, devices, diagnostics, patient recruitment, and trial design and execution.
Labcorp respects your privacy.